Literature DB >> 19189074

Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.

Mark Luedde1, Ulrich Flögel, Maike Knorr, Christina Grundt, Hans-Joerg Hippe, Benedikt Brors, Derk Frank, Uta Haselmann, Claude Antony, Mirko Voelkers, Juergen Schrader, Patrick Most, Bjoern Lemmer, Hugo A Katus, Norbert Frey.   

Abstract

Hypertrophic cardiomyopathy (HCM) is associated with cardiac hypertrophy, diastolic dysfunction, and sudden death. Recently, it has been suggested that inefficient energy utilization could be a common molecular pathway of HCM-related mutations. We have previously generated transgenic Sprague-Dawley rats overexpressing a truncated cardiac troponin T (DEL-TNT) molecule, displaying typical features of HCM such as diastolic dysfunction and an increased susceptibility to ventricular arrhythmias. We now studied these rats using 31P magnetic resonance spectroscopy (MRS). MRS demonstrated that cardiac energy metabolism was markedly impaired, as indicated by a decreased phosphocreatine to ATP ratio (-31%, p < 0.05). In addition, we assessed contractility of isolated cardiomyocytes. While DEL-TNT and control cardiomyocytes showed no difference under baseline conditions, DEL-TNT cardiomyocytes selectively exhibited a decrease in fractional shortening by 28% after 1 h in glucose-deprived medium (p < 0.05). Moreover, significant decreases in contraction velocity and relaxation velocity were observed. To identify the underlying molecular pathways, we performed transcriptional profiling using real-time PCR. DEL-TNT hearts exhibited induction of several genes critical for cardiac energy supply, including CD36, CPT-1/-2, and PGC-1alpha. Finally, DEL-TNT rats and controls were studied by radiotelemetry after being stressed by isoproterenol, revealing a significantly increased frequency of arrhythmias in transgenic animals. In summary, we demonstrate profound energetic alterations in DEL-TNT hearts, supporting the notion that inefficient cellular ATP utilization contributes to the pathogenesis of HCM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189074     DOI: 10.1007/s00109-008-0436-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

1.  The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity.

Authors:  Larry S Tobacman; Mahta Nihli; Carol Butters; Mark Heller; Victoria Hatch; Roger Craig; William Lehman; Earl Homsher
Journal:  J Biol Chem       Date:  2002-05-14       Impact factor: 5.157

2.  Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?

Authors:  T Tanaka; K Sohmiya; K Kawamura
Journal:  J Mol Cell Cardiol       Date:  1997-01       Impact factor: 5.000

3.  Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes.

Authors:  K Sakata; H Ino; N Fujino; M Nagata; K Uchiyama; K Hayashi; T Konno; M Inoue; H Kato; Y Sakamoto; T Tsubokawa; M Yamagishi
Journal:  Heart       Date:  2008-10       Impact factor: 5.994

4.  Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation.

Authors:  Murali Chandra; Matthew L Tschirgi; Jil C Tardiff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-01       Impact factor: 4.733

5.  The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes.

Authors:  R B Vega; J M Huss; D P Kelly
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

6.  Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias.

Authors:  N Frey; W M Franz; K Gloeckner; M Degenhardt; M Müller; O Müller; H Merz; H A Katus
Journal:  Cardiovasc Res       Date:  2000-08       Impact factor: 10.787

Review 7.  Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.

Authors:  Houman Ashrafian; Charles Redwood; Edward Blair; Hugh Watkins
Journal:  Trends Genet       Date:  2003-05       Impact factor: 11.639

8.  Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.

Authors:  Björn C Knollmann; Paulus Kirchhof; Syevda G Sirenko; Hubertus Degen; Anne E Greene; Tilmann Schober; Jessica C Mackow; Larissa Fabritz; James D Potter; Martin Morad
Journal:  Circ Res       Date:  2003-02-06       Impact factor: 17.367

9.  Autopsy findings in siblings with hypertrophic cardiomyopathy caused by Arg92Trp mutation in the cardiac troponin T gene showing dilated cardiomyopathy-like features.

Authors:  Masami Shimizu; Hidekazu Ino; Masato Yamaguchi; Hidenobu Terai; Katsuharu Uchiyama; Masaru Inoue; Masatoshi Ikeda; Atsuhiro Kawashima; Hiroshi Mabuchi
Journal:  Clin Cardiol       Date:  2003-11       Impact factor: 2.882

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  14 in total

Review 1.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

2.  The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling.

Authors:  Franziska Dierck; Christian Kuhn; Claudia Rohr; Susanne Hille; Julia Braune; Samuel Sossalla; Sibylle Molt; Peter F M van der Ven; Dieter O Fürst; Norbert Frey
Journal:  J Biol Chem       Date:  2017-07-17       Impact factor: 5.157

Review 3.  Mechanisms of disease: hypertrophic cardiomyopathy.

Authors:  Norbert Frey; Mark Luedde; Hugo A Katus
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

Review 4.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

5.  Delineation of Molecular Pathways Involved in Cardiomyopathies Caused by Troponin T Mutations.

Authors:  Jennifer E Gilda; Xianyin Lai; Frank A Witzmann; Aldrin V Gomes
Journal:  Mol Cell Proteomics       Date:  2016-03-28       Impact factor: 5.911

Review 6.  Mechanotransduction and Metabolism in Cardiomyocyte Microdomains.

Authors:  Francesco S Pasqualini; Alexander P Nesmith; Renita E Horton; Sean P Sheehy; Kevin Kit Parker
Journal:  Biomed Res Int       Date:  2016-12-04       Impact factor: 3.411

Review 7.  Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Authors:  Corrado Poggesi; Carolyn Y Ho
Journal:  J Muscle Res Cell Motil       Date:  2014-02-04       Impact factor: 2.698

8.  Hypothesis and theory: mechanical instabilities and non-uniformities in hereditary sarcomere myopathies.

Authors:  Alf Månsson
Journal:  Front Physiol       Date:  2014-09-15       Impact factor: 4.566

9.  Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression.

Authors:  Matthias Eden; Benjamin Meder; Mirko Völkers; Montatip Poomvanicha; Katrin Domes; M Branchereau; P Marck; Rainer Will; Alexander Bernt; Ashraf Rangrez; Matthias Busch; Martin Hrabě de Angelis; Christophe Heymes; Wolfgang Rottbauer; Patrick Most; Franz Hofmann; Norbert Frey
Journal:  Nat Commun       Date:  2016-04-28       Impact factor: 14.919

10.  Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.

Authors:  Shishi Li; Huaye Pan; Chao Tan; Yaping Sun; Yanrui Song; Xuan Zhang; Wei Yang; Xuexiang Wang; Dan Li; Yu Dai; Qiang Ma; Chenming Xu; Xufen Zhu; Lijun Kang; Yong Fu; Xuejun Xu; Jing Shu; Naiming Zhou; Feng Han; Dajiang Qin; Wendong Huang; Zhong Liu; Qingfeng Yan
Journal:  Stem Cell Reports       Date:  2018-02-15       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.